Prosecution Insights
Last updated: November 04, 2026
Application No. 18/796,295

BLOOD TEST DEVICE

Non-Final OA §103§112
Filed
Aug 07, 2024
Priority
Feb 24, 2022 — continuation of PCTJP2022007627
Examiner
WRIGHT, PATRICIA KATHRYN
Art Unit
1798
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Cellspect Co. Ltd.
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
1y 3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
607 granted / 930 resolved
At TC average
Strong +42% interview lift
Without
With
+42.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
43 currently pending
Career history
986
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
37.8%
-2.2% vs TC avg
§102
22.7%
-17.3% vs TC avg
§112
32.8%
-7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 930 resolved cases

Office Action

§103 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) submitted on August 07, 2024 follows the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1, line 7 recites “the second surface” but does not clearly identify which surface to which it is referring. This lacks antecedent basis. Similarly, the “first opening” appears to identify itself with an opening on the first substate. The examiner recommends changing “the first opening” to --a first opening-- for clarity. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 2, 4, 6, 7, and 8 are rejected under 35 U.S.C. 103 as being unpatentable over Iketani (US 20080003141) in view of Chan et al. (US20040002063; hereinafter “Chan”). Iketani teaches a blood test device 1 for measuring the presence or concentration of a specific substance in blood based on a color reaction that occurs in a dry reagent phase impregnated with a reagent by bringing plasma separated from the blood into contact with the dry reagent phase (see abstract and Figs 1-3 and 10), comprising: a first substrate 12 with the first opening 15 where the blood is to be added (see para [0070] et seq.); a second substrate 11 arranged opposite the first substrate, with a second opening 16 to observe the color reaction (see Fig. 1-3); the dry reagent phase 17 laminated on the second surface between the first substrate 12 and the second substrate 11 so that a part of the dry reagent phase is exposed from the second opening (see para [0072] et seq.); a plasma separation part 13a, 13b formed by a porous sheet material and laminated on the dry reagent phase (filter layers 13a and 13b above reagent layer 17, Figure 10 and paras [0070]-[0083]); and a diffusion layer (spreading layer 18) formed by a sheet of hydrophilic fibers and arranged on the plasma separation part so that a part of the diffusion layer is exposed from the first opening (corresponds to spreading layer 18, for which lketani teaches as an example rayon, above filters 13a/13b and exposed through opening 15, see Fig. 10 and para [0083] et seq.) Iketani does not disclose an area of a surface of the plasma separation part on (facing) the dry reagent phase side, the area being outside a section in contact with the dry reagent phase, being bonded to the second substrate (interpreted by the examiner to mean the plasma separator reagent facing surface is bonded to the second substate outside the portion containing the dry reagent phase). Chan is directed to support and fluid transport in blood-separation testing devices. Chan teaches a blood separation zone 100 having a first end whole blood (see para [0055]) carrier 103 affixed to its lower surface. The carrier provides mechanical support and reduces seepage during transport of the separated fluid toward reaction zone 5. Chan expressly permits direct or indirect attachment using adhesive (see Fig. 5, para [0056], [0094]). Additionally, Chan teaches maintaining fluid transferring contact between separate end 102 and reaction zone 5, see para [0055] et seq.) It would have been obvious prior to the effective filing date of the claimed invention to apply Chan's adhesive attachment of the blood separator to an underlying support to Iketani's filter layer 13 and substrate 11. The attachment would be located on the reagent facing surface of filter layer of Iketani, in a peripheral area extending beyond reagent layer 17, with adhesive spanning the separation from substrate. This placement would secure the separator while leaving the separator to reagent contact region unobstructed for plasma transfer. The reason for the modification is Chan's stated benefit of supporting the blood separator and reducing seepage, while preserving the fluid transfer required by Iketani's assay. Iketani independently permits adhesive assembly of its layered components (para [0076]). A person of ordinary skill would therefore have reasonably expected an adhesive attachment outside the active reagent-contact region to secure the separator without blocking its operative plasma-transfer interface. Regarding claim 2, Iketani teaches a ratio of the volume of the plasma separation part to the volume of the dry reagent phase between 1.6 and 3.7 times, inclusive. Specifically, Iketani teaches the reagent layer 17 having dimensions of 5-7 mm X 5-7 mm X 0.1-0.2 mm, filter 13a dimensions are preferably 5-7 mm X 5-7 mm X 0.2-0.3 mm and filter 13b are preferably 5-7 mm X 5-7 mm X 0.3-0.4 mm. The calculated nominal separator volume includes both filters, not the spreading layer substrate, adhesive or spacer: V13a = 6.5 x 6.5 x 0.2 = 8.450 mm3; V13b = 6.5 x 6.5 x 0.3 = 12.675 mm3; Vseparator = 8.450 + 12.675 = 21.125 mm3. Vreagent = 6 x 6 x 0.2 = 7.2 mm3 . Therefore, Therefore Iketani teaches the ratio of Vseparator / Vreagent = 21.125 / 7.200 = 2.9, and 1.6 <2.9 < 3.7. This calculation establishes that this configuration falls within claim 2. The proposed reason for selecting these dimensions is to provide a compact reagent area beneath a slightly larger separator, using the preferred dimensional options and retaining a peripheral attachment margin. A centered 6 mm reagent pad under a 6.5 mm separator leaves (6.5 - 6) /2 = 0.25 mm on each side. Chan's support and seepage rationale applies to attachment in that margin. The expected success is mechanical retention with an unobstructed active fluid-transfer region. Regarding claim 4, the dimensional selection and rationale applied with respect to claim 2 above applies to a ratio between 2.0 and 3.1 times. The reasoning discussed in claim 2 for the dimensional selection are incorporated herein. Regarding claim 6, Iketani’s device includes spacer with a predetermined height arranged between the first substrate and the second substrate forming a space therebetween, wherein the dry reagent phase, the plasma separation part, and the diffusion layer are arranged in the space, and the height of the spacer is less than the sum of the thickness of the diffusion layer, the thickness of the plasma separation part, and the thickness of the dry reagent phase, in the state before assembly of the blood test device. Specifically, Iketani teaches a spacer 14, first substrate 12, second substrate 11, reagent phase 17, filters 13a/13b, and spreading layer 18 and the spacer thinner than the pre-compressed reagent and filter stack and compresses spreading layer 18 in that stack (see Figs. 6-11 and para [0082] et seq.) Regarding claim 7, Iketani teaches the spacer layer 14 has a rectangular planar shape, its dimensions are in the range of, for example, 3 to 10 mm long by 3 to 10 mm wide by 0.5 to 1.2 mm thick, preferably 4 to 8 mm long by 4 to 8 mm wide by 0.6 to 1.0 mm thick, and more preferably 5 to 7 mm long by 5 to 7 mm wide by 0.7 to 0.9 mm thick, although the spacer is not limited to these dimensions (see para [0074] et seq.) The reason for the spacer arrangement is to maintain the compressed layered assembly while the added peripheral attachment of Chan supports the separator outside the active transfer region. It would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to determine the desired thickness , since it has been held that the provision of adjustability, where needed, involves only routine skill in the art, see MPEP 2144.04 (V) (D). Regarding claim 8, Iketani teaches the plasma separation part includes a polysulfone membrane (see para [0080] et seq.) Claims 3 and 5 are rejected under 35 U.S.C. 103 as being unpatentable over Iketani and Chan as applied to claim 1 above, in further view of Tanaka et al., (US 20090145840; hereinafter “Tanaka”). Regarding claim 3, the combination of Iketani and Chan teaches that the ratio of the volume of the plasma separation part to the sum of the volumes of the dry reagent phases is between 1.6 times and 3.7 times. Iketani teaches the impregnated and dried reagent material (see para [0095] and Fig. 9). However the combination does not explicitly disclose a plurality of the second openings and dry reagent phases are provided in the device (interpreted as the same device). In the art of blood separating/testing devices, Tanaka discloses a supporter 97 with three through holes corresponding to reagent layers 851, 852, and 853 on common blood separation membrane 86. Tanaka recognizes the benefit of analysis of multiple test items, see para [0092] and [0095]. The modification would replace Iketani's single reagent pad 17 with separate dry reagent pads and to provide a respective measurement opening 16 in substrate 11 for each pad, following Tanaka's teaching of pad and opening arrangement. It would have been obvious to one of ordinary skill in the art prior to the effective filing date of the claimed invention to include in the combination of Iketani and Chan a plurality of reagent pad and respective openings in order to analyze more than one blood constituent in a single device as recognized in Tanaka (see para [0095] et seq.) A skilled person would have expected plasma from the common separator to contact respective reagent pads and their color reactions to remain observable through corresponding openings. Regarding claim 5, Iketani teaches the volume ratio of plasma separation part to the dry reagent phase, as set forth above. Tanaka teaches a multi-item analysis device with a plurality of dry reagent areas and observation openings. It would have been obvious to modify the combination of Iketani and Chan with the teachings of Tanaka for the reasons delineated above with respect to claim 3. Citations to art In the above citations to documents in the art, an effort has been made to specifically cite representative passages, however rejections are in reference to the entirety of each document relied upon. Other passages, not specifically cited, may apply as well. Pertinent Prior Art The following prior art is hereby made of record. Although the prior art is relied upon, the examiner considers the listed prior art relevant to the applicant’s invention and may be relied upon in a future prior art rejection or as general background information related to applicant’s field of endeavor. i. Wilson et al., (US 2017/0241977) teach a blood test device including a second surface 56 of the separation membrane 42 may contact the adhesive member 44. In some embodiments, the adhesive member 44 may prevent leakage of blood cells around the perimeter of the separation membrane 42 (see at least para [0043] et seq.) ii. Anaokar et al., (US 20050003523) teach a blood test device including a blood separation layer 40, multiple assay stacks 42, and corresponding reading openings 34 (see Figs. 2-5). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to P. Kathryn Wright whose telephone number is (571)272-2374. The examiner can normally be reached between 9:30am-7pm EST. Examiner interviews are available via telephone and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. E-mail communication Authorization Per updated USPTO Internet usage policies, Applicant and/or applicant’s representative is encouraged to authorize the USPTO examiner to discuss any subject matter concerning the above application via Internet e-mail communications. See MPEP 502.03. To approve such communications, Applicant must provide written authorization for e-mail communication by submitting the following statement via EFS Web (using PTO/SB/439) or Central Fax (571-273-8300): Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with the undersigned and practitioners in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application by video conferencing, instant messaging, or electronic mail. I understand that a copy of these communications will be made of record in the application file. Written authorizations submitted to the Examiner via e-mail are NOT proper. Written authorizations must be submitted via EFS-Web (using PTO/SB/439) or Central Fax (571-273-8300). A paper copy of e-mail correspondence will be placed in the patent application when appropriate. E-mails from the USPTO are for the sole use of the intended recipient, and may contain information subject to the confidentiality requirement set forth in 35 USC § 122. See also MPEP 502.03. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles Capozzi can be reached on 571-270-3638. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /P. Kathryn Wright/Primary Examiner, Art Unit 1798
Read full office action

Prosecution Timeline

Aug 07, 2024
Application Filed
Oct 05, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779456
ONE-STATION BIOMEDICAL MICRO LABORATORY SYSTEM AND OPERATION METHOD THEREOF
2y 10m to grant Granted Nov 03, 2026
Patent 12768850
LABORATORY AUTOMATION DEVICE WITH TRANSPARENT DISPLAY IN DOOR
3y 10m to grant Granted Oct 20, 2026
Patent 12768856
AUTOMATED INTERPRETATION SYSTEM FOR QUANTITATIVE AND QUALITATIVE ANALYSIS OF BIOCHIPS
2y 9m to grant Granted Oct 20, 2026
Patent 12729361
Culture Structure, Culture Method and Culture Chip
3y 3m to grant Granted Sep 08, 2026
Patent 12716906
AUTOMATIC ANALYZER, DISPENSING DEVICE, AND DISPENSING CONTROL METHOD
3y 11m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+42.2%)
3y 6m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 930 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month